Adolore Biotherapeutics, Inc.

PRESS RELEASE

published on 05/16/2024 at 16:00, 1 year 9 months ago

Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels
Adolore BioTherapeutics announces groundbreaking findings in gene therapy for chronic pain treatment, highlighting the value of non-opioid analgesics and progress with IND-enabling studies

Adolore BioTherapeutics Chronic Pain Gene Therapy Non-opioid Analgesics IND-enabling Studies
BRIEF

published on 03/04/2024 at 16:05, 1 year 11 months ago

Adolore BioTherapeutics obtient un brevet américain pour la thérapie génique CA8* dans le traitement de la douleur chronique

Adolore BioTherapeutics Thérapie Génique Traitement De La Douleur Chronique Solutions Sans Opioïdes Délivrance De Brevet
BRIEF

published on 03/04/2024 at 16:05, 1 year 11 months ago

Adolore BioTherapeutics Secures U.S. Patent for CA8* Gene Therapy in Chronic Pain Treatment

Adolore BioTherapeutics Gene Therapy Chronic Pain Treatment Opioid-Free Solutions Patent Issuance
PRESS RELEASE

published on 03/04/2024 at 16:00, 1 year 11 months ago

Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain
Adolore BioTherapeutics licenses patent and CA8* gene therapy technology from the University of Miami for opioid-free chronic pain treatment. Company progresses toward clinical testing and commercialization

University Of Miami Adolore BioTherapeutics Chronic Pain Opioid-free Gene Therapy
PRESS RELEASE

published on 01/30/2024 at 16:00, 2 years ago

Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting
Adolore BioTherapeutics will present at the 5th Annual NIH HEAL Initiative Scientific Meeting regarding the gene therapy program for chronic pain associated with knee osteoarthritis. The program is supported by NIH/NINDS HEAL UH3 Award

Adolore BioTherapeutics Chronic Pain NIH HEAL Initiative Gene Therapy Osteoarthritis
PRESS RELEASE

published on 12/05/2023 at 16:30, 2 years 2 months ago

Adolore BioTherapeutics Presents Promising Preclinical Data Supporting Its Innovative Gene Therapy to Treat Chronic Pain
Adolore BioTherapeutics presented preclinical data supporting its innovative CA8* gene therapy as a long-acting local analgesic for chronic osteoarthritis knee pain management, aiming to replace opioids

Adolore BioTherapeutics CA8* Gene Therapy Chronic Pain Opioid-free Preclinical Data
PRESS RELEASE

published on 10/11/2023 at 16:00, 2 years 4 months ago

Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference
PRESS RELEASE

published on 10/03/2023 at 15:15, 2 years 4 months ago

NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal Investigator Roy C. Levitt M.D, to Fund Clinical Development of Adolore BioTherapeutics’ Gene Therapy Program for the Treatment of Chronic Osteoarthritis Knee Pain

Published on 02/20/2026 at 20:15, 12 minutes ago

Lithium South Announces Results of its Annual and Special Meeting of Securityholders
Published on 02/20/2026 at 20:15, 12 minutes ago

Verdera Energy Announces Closing of Qualifying Transaction
Published on 02/20/2026 at 18:30, 1 hour 57 minutes ago

Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 4 hours 42 minutes ago

Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 5 hours 57 minutes ago

Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant

View all ACCESSWIRE

Published on 02/20/2026 at 18:36, 1 hour 51 minutes ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 1 hour 56 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:23, 2 hours 4 minutes ago

POS-Transaction in Own Shares
Published on 02/20/2026 at 18:00, 2 hours 27 minutes ago

Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 2 hours 27 minutes ago

Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations

View all EQS

Published on 02/20/2026 at 19:29, 58 minutes ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 58 minutes ago

SFPI GROUP: bilan du contrat de liquidité S2 S025
Published on 02/20/2026 at 18:00, 2 hours 27 minutes ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 18:00, 2 hours 27 minutes ago

TERACT - Résiliation du contrat de liquidité
Published on 02/20/2026 at 17:35, 2 hours 52 minutes ago

CHIFFRE D'AFFAIRES 2025

View all LES ECHOS COMFI WIRE

News